Clinical Trials Browser

Phase 1/2 × Salivary Gland Neoplasms × RC48 antibody × Clear all

NCT05898373 2023-06-12

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Phase 1/2 Not yet recruiting

Salivary Gland Neoplasms